Allergan plc, a leading global pharmaceutical company, and Rugen Therapeutics, a start-up biotechnology company focused on the development of novel treatments for unmet CNS disorders and funded by the F-Prime Biomedical Research Initiative, today announced that they have entered into an exclusive collaboration to support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).
Publication in Nature Cell Biology: researchers at the Université libre de Bruxelles – ULB Cancer Research Center, U-CRC – show the causal link between aneuploidy and cancer.
Researchers reveal causal association between aneuploidy and cancer
Analysis from business intelligence provider GBI Research – Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 – states that the global market value for T1DM treatment will rise from $4.2 billion in 2014 to $7.1 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 7.9%.
See original article:
T1DM therapeutics market expected to reach $7.1 billion by 2021
Team Health Holdings, Inc., a leading physician services organization, today announced it has successfully completed its acquisition of IPC Healthcare, Inc., a national acute hospitalist and post-acute provider organization.
Children with amblyopia, commonly known as “lazy eye,” may have impaired ocular motor function. This can result in difficulties in activities for which sequential eye movements are important, such as reading.
CRISPR is one of the most exciting advances in gene-based medicine in decades. A uniquely powerful tool for editing the genome, it allows scientists to manipulate DNA with unprecedented precision by deleting unwanted or faulty genes and replacing them with different ones. Its promise in this field of medicine is immense, unlocking the potential for novel treatments across a wide range of therapeutic areas.
Virginia Mason Medical Center is using a $25,000 grant from the Cardinal Health Foundation to support a pilot program designed to reduce hospital readmissions among patients diagnosed with heart failure.